Skip to main content
SpringerLink
Log in

Clinical Features

  • Chapter
  • First Online:
Handbook of Hepatitis C

  • 1047 Accesses

Abstract

Hepatitis C virus (HCV) infection is generally paucisymptomatic, except during the later stages of disease when complications of chronic HCV infection such as liver decompensation and hepatocellular carcinoma (HCC) occur. In this chapter we review the clinical features associated with acute and chronic HCV infection, including extrahepatic manifestations, and discuss factors associated with disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008;49:625–633.

    Google Scholar 

  2. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88.

    Google Scholar 

  3. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36 (Suppl 1):S35–46.

    Google Scholar 

  4. Negro F. Hepatitis C Virus Epidemiology, Pathogenesis, Diagnosis, and Natural History. In: Zeuzem S, Afdhal NH, editors. inPractice Hepatology. 2015.

    Google Scholar 

  5. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418–431.

    Google Scholar 

  6. Wiese M, Fischer J, Löbermann M, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology. 2014;59:49–57.

    Google Scholar 

  7. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–472.

    Google Scholar 

  8. Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54:396–405.

    Google Scholar 

  9. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273.

    Google Scholar 

  10. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61 (Suppl 1):S79–90.

    Google Scholar 

  11. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593.

    Google Scholar 

  12. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271–278.

    Google Scholar 

  13. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61 (Suppl 1):S69–78.

    Google Scholar 

  14. Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40:823–830.

    Google Scholar 

  15. Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. Gastroenterology. 2015;149:1345–1360.

    Google Scholar 

  16. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Eng J Med. 2013;369:1035–1045.

    Google Scholar 

  17. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010–2017.

    Google Scholar 

  18. Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125:1723–1732.

    Google Scholar 

  19. Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120:1034–1041.

    Google Scholar 

  20. Goossens N, Negro F. Insulin Resistance, non-alcoholic fatty liver disease and hepatitis C virus infection. Rev Recent Clin Trials. 2014;9:204–209.

    Google Scholar 

  21. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49:831–844.

    Google Scholar 

  22. Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008;48:721–727.

    Google Scholar 

  23. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369–380.

    Google Scholar 

  24. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102:570–576.

    Google Scholar 

  25. Moucari R, Forestier N, Larrey D, et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut. 2010;59:1694–1698.

    Google Scholar 

  26. Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 2003;39:620–627.

    Google Scholar 

  27. Gemignani F, Brindani F, Alfieri S, et al. Clinical spectrum of cryoglobulinaemic neuropathy. J Neuro Neurosurg Psychiatry. 2005;76:1410–1414.

    Google Scholar 

  28. Poynard T, Cacoub P, Ratziu, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002;9:295–303.

    Google Scholar 

  29. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433–439.

    Google Scholar 

  30. Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57:1379–1390.

    Google Scholar 

  31. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. 2008;49:9–16.

    Google Scholar 

  32. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51:655–666.

    Google Scholar 

  33. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59:2403–2412.

    Google Scholar 

  34. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepatitis. 2011;18:e516–522.

    Google Scholar 

  35. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–1642.

    Google Scholar 

  36. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology. 2004;40:1426–1433.

    Google Scholar 

  37. Rüeger S, Bochud PY, Dufour JF, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2015;64:1605–1615.

    Google Scholar 

  38. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805–809.

    Google Scholar 

  39. Freedman ND, Everhart JE, Lindsay KL, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009;50:1360–1369.

    Google Scholar 

  40. Cardin R, Piciocchi M, Martines D, Scribano L, Petracco M, Farinati F. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis. 2013;45:499–504.

    Google Scholar 

  41. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22:1979–1991.

    Google Scholar 

  42. Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. HCV in liver transplantation. Semin Immunopathol. 2013;35:101–110.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, USA

    Nicolas Goossens

  2. Department of Clinical Pathology, Faculty of Medicine, Geneva University Hospitals, Geneva, Geneve, Switzerland

    Sophie Clément

  3. Geneva University Hospitals, Geneva, Geneve, Switzerland

    Francesco Negro

Authors
  1. Nicolas Goossens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Clément
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Negro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA

    Nicolas Goossens

  2. University Hospitals and Faculty of Medi, Clinical Pathology, Geneva, Geneve, Switzerland

    Sophie Clément

  3. Division of Gastroenterology and Hepatol, Geneva University Hospital, Geneva 14, Geneve, Switzerland

    Francesco Negro

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Goossens, N., Clément, S., Negro, F. (2016). Clinical Features. In: Goossens, N., Clément, S., Negro, F. (eds) Handbook of Hepatitis C . Adis, Cham. https://doi.org/10.1007/978-3-319-28053-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28053-0_3

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-28051-6

  • Online ISBN: 978-3-319-28053-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation